Table 1 Patient characteristics Patient... | American Society of Hematology

Table 1

Patient characteristics

Patient no.	Age, y	Sex	Interval from diagnosis to autologous treatment, mo	Stage at treatment	Donor	EBMT score	Pretreatment
1	60	Male	144	AP	Unrelated	5	HU, IF, IM
2	48	Female	34	1. CP	Unrelated	4	IM, IF
3	42	Female	202	2. CP	Sibling	5	HU, IM
4	56	Male	9	AP	Sibling	3	IM
5	33	Male	15	1. CP	Sibling	2	IM
6	34	Female	16	1. CP	Sibling	2	IM
7	66	Male	18	AP (T315I)	Unrelated	5	IM, DA
8	40	Male	12	1. CP	Unrelated	2	HU, IM
9	55	Female	42	AP	Sibling	4	IM, HU
10	67	Male	124	2. CP	Sibling	5	PCT, autologous transplantation, IM, DA
11	39	Female	14	1. CP	Unrelated	3	IM
12	41	Female	38	1. CP	Sibling	3	IM
13	21	Male	21	1. CP	Unrelated	3	HU, IM
14	66	Male	27	2. CP	Unrelated	6	HU, IF, IM, PCT, DA

Patient no.	Age, y	Sex	Interval from diagnosis to autologous treatment, mo	Stage at treatment	Donor	EBMT score	Pretreatment
1	60	Male	144	AP	Unrelated	5	HU, IF, IM
2	48	Female	34	1. CP	Unrelated	4	IM, IF
3	42	Female	202	2. CP	Sibling	5	HU, IM
4	56	Male	9	AP	Sibling	3	IM
5	33	Male	15	1. CP	Sibling	2	IM
6	34	Female	16	1. CP	Sibling	2	IM
7	66	Male	18	AP (T315I)	Unrelated	5	IM, DA
8	40	Male	12	1. CP	Unrelated	2	HU, IM
9	55	Female	42	AP	Sibling	4	IM, HU
10	67	Male	124	2. CP	Sibling	5	PCT, autologous transplantation, IM, DA
11	39	Female	14	1. CP	Unrelated	3	IM
12	41	Female	38	1. CP	Sibling	3	IM
13	21	Male	21	1. CP	Unrelated	3	HU, IM
14	66	Male	27	2. CP	Unrelated	6	HU, IF, IM, PCT, DA

EBMT indicates European Group for Blood and Marrow Transplantation; CP, chronic phase; AP, accelerated phase; T315I, P-loop mutation of Bcr-Abl; HU, hydroxyurea; IF, interferon; DA, dasatinib; Tx, autologous transplantation; and PCT, polychemotherapy.

View Large

This Feature Is Available To Subscribers Only